Industry
Foghorn cuts 40% of workforce after Lilly collaboration ends
Foghorn Therapeutics is laying off 40% of its workforce after Eli Lilly ended their drug development collaboration.
The original reports on this story are listed below.
More top stories
Outbreaks
Pennsylvania reports fifth measles-associated death
The unvaccinated Lancaster County resident is Pennsylvania’s fifth reported measles-associated death this year.
Diabetes and obesity
Lilly reports 23.3% weight loss with eloralintide-tirzepatide combo
The highest-dose combination produced greater weight loss than tirzepatide alone, but up to 27% of participants stopped treatment because of side effects.
Drugs and FDA
Survodutide cut weight by up to 9.8% in adults with diabetes and obesity
In the 76-week trial, gastrointestinal side effects led 18% of participants in each survodutide dose group to stop treatment.